In this review, we describe insights into ␤-amyloid (A␤) production using aged dogs as a model of human brain aging. The advantage of using dogs is that they naturally accumulate A␤ neuropathology with age. In parallel, dogs also develop age-associated learning and memory impairments. Thus, dogs can complement existing transgenic and nonhuman primate models typically used in aging studies. Dogs can live up to 18 -19 years of age and companion dogs share the same environment as humans. Morphological brain changes as a function of age are clearly visible in vivo using magnetic image resonance scans. At the light microscopic level, dogs accumulate diffuse plaques with a distribution similar to that observed in human brain. Confocal studies suggest that A␤ accumulates on neuronal membranes in a segregated pattern. This pattern has been confirmed at the ultrastructural level using electron microscopy and provides insight into the deposition of A␤ into the extracellular space, possibly prior to overt plaque formation. Further, double immunogold labeling studies demonstrate that A␤ associated with the plasma membrane is colocalized with presenilin. These in vivo observations suggest a common site for both A␤ and presenilin supporting the hypothesis that the latter is involved with APP processing. © 2002 Elsevier Science (USA)
INTRODUCTION
Alzheimer's disease (AD) 3 is becoming a national health crisis as the incidence of this disease is rising in parallel with the growth of our elderly population. The human and financial consequences of this disease are devastating. AD is associated with a progressive cognitive decline, usually starting with memory difficulties early in the disease and leading to gross functional impairments (Morris, 1988) . The diagnosis of AD cannot be made with certainty until postmortem examination and extensive senile plaque accumulation and neurofibrillary tangle formation are observed (Khachaturian, 1985; Mirra et al., 1991 ; The National Institute on Aging, 1997).
Familial AD accounts for 20 -50% of all cases under the age of 60 years, i.e., early onset AD (Zabar, 2000) . Identifying the genetic basis of familial AD has been a significant advance in the field. Mutations on chromosomes 1 (presenilin-2), 14 (presenilin-1), and 21 (amyloid precursor protein) all lead to the enhanced production of ␤-amyloid peptide (A␤), particularly the longer 42/43 amino acid species (Duff, 1996; Borchelt, 1997; Citron, 
